Senesco's Preclinical Multiple Myeloma Data Presented at the 50th Annual Meeting of the American Society of Hematology

Tuesday, December 9, 2008 General News
Email Print This Page Comment bookmark
Font : A-A+

NEW BRUNSWICK, N.J., Dec. 9 Senesco Technologies, Inc. ("Senesco" or the "Company") (NYSE Alternext US: SNT) announced today that John A. Lust, M.D., Ph.D., Associate Professor of Hematology at Mayo Clinic, Rochester, MN, and the principal investigator of Senesco's multiple myeloma-focused preclinical studies, presented data from these studies at the 2008 Annual Meeting of the American Society of Hematology, which is being held at the Moscone Center in San Francisco, CA, from December 6 through December 9, 2008.

Dr. Lust's presentation, entitled "Preclinical Studies Using Polyethylenimine (PEI) Nanoparticles Complexed with Eukaryotic Translation Initiation Factor 5A (eIF5A) siRNA and eIF5A Plasmid DNA Demonstrates Significant Anti-Myeloma Activity in Vitro and in Vivo", took place during the "Pathophysiology and Translational Models" session, on Monday, December 8, 2008.

Held annually in December, the American Society of Hematology's annual meeting provides hematologists from around the world a forum for discussing critical issues in hematology. More than 21,000 clinicians, scientists and others attend the four-day meeting. The annual meeting features oral and poster presentations that are chosen by peer-reviewers from abstracts submitted prior to the meeting and contain the latest and most exciting developments in scientific research. Plenary symposia and named lectures on specialized areas of hematology are also presented throughout the meeting program.

About Senesco Technologies, Inc.

Senesco Technologies, Inc. is a U.S. biotechnology company, headquartered in New Brunswick, NJ. Senesco has initiated preclinical research to trigger or delay cell death in mammals (apoptosis) to determine if the technology is applicable in human medicine. Accelerating apoptosis may have applications to development of cancer treatments. Delaying apoptosis may have applications to certain diseases inflammatory and ischemic diseases. Senesco takes its name from the scientific term for the aging of plant cells: senescence. Delaying cell breakdown in plants extends freshness after harvesting, while increasing crop yields, plant size and resistance to environmental stress. The Company believes that its technology can be used to develop superior strains of crops without any modification other than delaying natural plant senescence. Senesco has partnered with leading-edge companies engaged in agricultural biotechnology and earns research and development fees for applying its gene-regulating platform technology to enhance its partners' products.

Certain statements included in this press release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from such statements expressed or implied herein as a result of a variety of factors, including, but not limited to: the development of the Company's gene technology; the approval of the Company's patent applications; the successful implementation of the Company's research and development programs and joint ventures; the success of the Company's license agreements; the acceptance by the market of the Company's products; success of the Company's preliminary studies and preclinical research; competition and the timing of projects and trends in future operating performance, our ability to maintain our continued listing standards for the next 12 months, as well as other factors expressed from time to time in the Company's periodic filings with the Securities and Exchange Commission (the "SEC"). As a result, this press release should be read in conjunction with the Company's periodic filings with the SEC. The forward-looking statements contained herein are made only as of the date of this press release, and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.

Company Contact: Investor Relations Contact: Senesco Technologies, Inc. FD Bruce Galton Brian Ritchie Chief Executive Officer ( ( (212) 850-5600 (732) 296-8400

SOURCE Senesco Technologies, Inc.

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store